Your cart

×
Note: As of September 30th there will be order processing and shipment delays that may last until October 8, 2020 as we are transitioning to a new ERP system. Please email information@gyrosproteintech.com to discuss what accommodations we can provide during this time.

Unlocking aggregation in amyloid peptides opens up Alzheimer’s research

Sep 30, 2019 9:00:00 AM

Alzheimer's is a progressive degenerative disease of the brain that accounts for 60–80% of dementia cases, which cover a range of cognitive disabilities including memory loss (1). Alzheimer's is the sixth leading cause of death in the United States, with an expected life expectancy of 4–8 years after diagnosis.This disease is not a normal part of aging, and approximately 200,000 Americans under the age of 65 have younger-onset Alzheimer’s disease. There is currently no cure, but symptoms can be treated and great efforts are being made worldwide to improve treatment, delay onset, and ultimately prevent the disease from developing.The amyloid beta peptides involved in Alzheimer’s disease are prone to aggregation, challenging both synthesis and purification. A group based in Auckland New Zealand therefore developed a method to reversibly introduce double linkers into the synthetic peptide that reduce aggregation and improve solubility, resulting in higher yields and purity. 

Read More

Topics: Peptide synthesis, Alzheimer's disease, Tribute peptide synthesizer, SPPS, Amyloid peptides, Pseudoproline

Overcoming opioid side effects with combination peptide therapy

Aug 20, 2019 8:30:00 AM

Unrelieved pain is a major global healthcare problem. There are two types of pain: acute pain, which is typical after surgery and trauma and chronic or recurring pain, which is common in individuals suffering from osteo- and rheumatoid arthritis, those with spine problems, and can be developed after operations and injuries. The problem is so great that chronic and recurrent pain is regarded as a disease in its own right. Apart from the burden of suffering, chronic pain results in a considerable cost to society that is on a par with cancer or cardiovascular disease by affecting one in five adults.

Opioids are the analgesics most prescribed to treat moderate to severe pain but their use leads to a number of debilitating side effects, diminishing efficacy, and also the risk of abuse and misuse. A research team at Université de Sherbrooke in Canada has investigated combining the prototypical opioid morphine and an analgesic neurotensin brain-penetrant peptide analog to treat pain. They discovered that co-administration resulted in an additive analgesic response that permitted the dosing of morphine to be reduced and also decreased the level of a typical adverse side effect, constipation.

Read More

Topics: Peptide synthesis, SPPS, Symphony peptide synthesizer, Combination peptide therapy, Pain treatment

5 factors to consider when choosing a peptide synthesizer

Apr 24, 2019 11:00:00 AM

Choosing a peptide synthesizer to meet your specific needs can be a daunting task. Here are some key factors to consider to be able to synthesize high quality peptides in the number and scale that matches your applications.

1. The question of throughput and parallel synthesis

Different applications and phases of research require different numbers of peptides. A peptide drug discovery program may involve screening hundreds (or even thousands) of peptides to find hits, followed by optimizing structure-activity relationships (SAR) with focused libraries to identify a single candidate that can be advanced to the clinic. The key to success is therefore to choose a synthesizer that has reaction vessels that can deliver the level of parallel synthesis you need to match your application1.

Read More

Topics: Prelude x, Symphony X, Peptide synthesis, Tribute, SPPS, Sonata XT, Real-time UV monitoring